PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-α), could be used to improve the selection of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes
Autori principali: Morieri, Mario Luca, Shah, Hetal S., Sjaarda, Jennifer, Lenzini, Petra A., Campbell, Hannah, Motsinger-Reif, Alison A., Gao, He, Lovato, Laura, Prudente, Sabrina, Pandolfi, Assunta, Pezzolesi, Marcus G., Sigal, Ronald J., Paré, Guillaume, Marcovina, Santica M., Rotroff, Daniel M., Patorno, Elisabetta, Mercuri, Luana, Trischitta, Vincenzo, Chew, Emily Y., Kraft, Peter, Buse, John B., Wagner, Michael J., Cresci, Sharon, Gerstein, Hertzel C., Ginsberg, Henry N., Mychaleckyj, Josyf C., Doria, Alessandro
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Diabetes Association 2020
Soggetti:
Genetics/Genomes/Proteomics/Metabolomics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7085251/
https://ncbi.nlm.nih.gov/pubmed/31974142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db19-0973
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi